Results 51 to 60 of about 289,170 (184)

MYCN Gene Copy Number Status Detected by FISH Method and Its Correlation with Outcome and Clinicopathological Variables in Childhood Neuroblastoma [PDF]

Middle East Journal of Cancer
Background: Neuroblastoma is the most common extracranial solid tumor in children. MYCN gene amplification (MNA) is an independent prognostic factor for rapid tumor progression and poor prognosis, regardless of age and clinical stage.
Mahdi Shahriari, Akbar Safaei, Parvaneh Davoudi, Bozorgmehr Hedayati   +3 more
doaj   +1 more source

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma [PDF]

, 2015
MYCN amplification occurs in 20% of neuroblastomas and is strongly related to poor clinical outcome. We have identified folate-mediated one-carbon metabolism as highly upregulated in neuroblastoma tumors with MYCN amplification and have validated this ...
Gherardi, S, Fischer, M, Perini, G, Juraeva, Dilafruz, Norris, Murray D, Marshall, Glenn M, Haber, Michelle, Juraeva, D, Ashton, LJ, Norris, MD ; https://orcid.org/, Marshall, GM, Fletcher, JI ; https://orcid.org/, GHERARDI, SAMUELE, Ashton, Lesley J., Lau, DT, Xue, Chengyuan, Oberthuer, André, PERINI, GIOVANNI, Flemming, CL, Xue, C, Lau, Diana T, Flemming, Claudia L, Fischer, Matthias, Oberthuer, A, Brors, B, Brors, Benedikt, Fletcher, Jamie I, Haber, M ; https://orcid.org/   +27 more
core   +1 more source

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma

Nature Communications, 2022
Half of high-risk neuroblastoma patients have MYCN amplification. Here, the authors show that MYCN induces fatty acid uptake and synthesis to support neuroblastoma and inhibition of a fatty acid transporter impairs tumor progression in preclinical models.
Ling Tao, Mahmoud A. Mohammad, Giorgio Milazzo, Myrthala Moreno-Smith, Tajhal D. Patel, Barry Zorman, Andrew Badachhape, Blanca E. Hernandez, Amber B. Wolf, Zihua Zeng, Jennifer H. Foster, Sara Aloisi, Pavel Sumazin, Youli Zu, John Hicks, Ketan B. Ghaghada, Nagireddy Putluri, Giovanni Perini, Cristian Coarfa, Eveline Barbieri   +19 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Engineered Allosteric Biosensor for In Situ DNA Glycosylase Detection in Neuroblastoma Risk Stratification and Drug Resistance Monitoring

Advanced Science, EarlyView.
An engineered allosteric biosensor (UUU‐DZ‐tFNA) was developed, in which UDG specifically recognizes and activates a DNAzyme to achieve signal cycle amplification in a sequentially activatable mode. UUU‐DZ‐tFNA achieves in situ UDG detection across multiple biological levels and facilitates risk stratification and drug resistance monitoring of NB ...
Yaqing Lu, Yingyu Zhang, Xianwei Zhang, Mengxin Zhang, Fei Zhang, Jushan Sun, Yahui Yang, Kangbo Liu, Peng Wang, Shuying Luo, Wancun Zhang   +10 more
wiley   +1 more source

The potential molecularly therapy target to MYCN‐amplificated neuroblastoma

Clinical and Translational Discovery, 2023
AbstractNeuroblastoma (NB) is an embryonal deadly cancer in childhood driven by MYC or MYCN‐driven oncogenic signaling. The amplification of MYCN leads to malignant progression of NB and poor prognosis. Traditional chemotherapy is still a standard treatment for NB. Most of the cytostatic drugs take function in anti‐neuroblastoma. However, children with
Susu Jiang, Xinxin Zhang, Jiaming Chang, Jinhong Zhu, Wenhan Yang, Jing He   +5 more
openaire   +2 more sources

Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma

Nature Communications, 2020
MYCN amplification is common in neuroblastomas. Here the authors analyse the MYCN amplicon structure and its epigenetic regulation by integrating short- and longread genomic and epigenomic data and find two classes of MYCN amplicons in neuroblastomas ...
Konstantin Helmsauer, Maria E. Valieva, Salaheddine Ali, Rocío Chamorro González, Robert Schöpflin, Claudia Röefzaad, Yi Bei, Heathcliff Dorado Garcia, Elias Rodriguez-Fos, Montserrat Puiggròs, Katharina Kasack, Kerstin Haase, Csilla Keskeny, Celine Y. Chen, Luis P. Kuschel, Philipp Euskirchen, Verena Heinrich, Michael I. Robson, Carolina Rosswog, Joern Toedling, Annabell Szymansky, Falk Hertwig, Matthias Fischer, David Torrents, Angelika Eggert, Johannes H. Schulte, Stefan Mundlos, Anton G. Henssen, Richard P. Koche   +28 more
doaj   +1 more source

MYCN Function in Neuroblastoma Development

Frontiers in Oncology, 2021
Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of MYCN is a single oncogenic driver inducing neoplastic transformation in neural crest ...
Jörg Otte, Cecilia Dyberg, Adena Pepich, John Inge Johnsen   +3 more
doaj   +1 more source

A Living Multi‐Omics PDX Biobank of High‐Risk Sarcomas Reveals ecDNA‐Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology

Advanced Science, EarlyView.
A living multi‐omics sarcoma PDX biobank is enriched for high‐risk disease and preserves key patient tumor features at histopathological and molecular levels. Integrated profiling reveals ecDNA‐driven oncogene amplification in osteosarcoma and preferential retention of ecDNA during PDX evolution.
Weisong Zhao, Zhiwei Cheng, Kai Tian, Mengxiong Sun, Zhuoying Wang, Ming Jiao, Jens Luebeck, Kaiyuan Zhu, Xiao Zhang, Dongqing Zuo, Hongsheng Wang, Chongren Wang, Jiakang Shen, Xiaojun Ma, Gangyang Wang, Zongyi Wang, Jing Han, Kaiyuan Liu, Haoran Mu, Weiqi Ma, Yongyong Ren, Shibing Guo, Huangxin Tu, Lingfeng Yu, Yining Tao, Yu Lv, Hui Lu, Owen S. Chapman, Rishaan Kenkre, Lukas Chavez, Zhengdong Cai, Yuqin Yang, Wei Sun, Yafei Jiang, Yingqi Hua   +34 more
wiley   +1 more source

Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma.

PLoS ONE, 2014
Neuroblastoma (NB) is the most common malignant disease of infancy. MYCN amplification is a prognostic factor for NB and is a sign of highly malignant disease and poor patient prognosis. In this study, we aimed to investigate novel MYCN-related genes and
Pei-Yi Wu, Yung-Feng Liao, Hsueh-Fen Juan, Hsuan-Cheng Huang, Bo-Jeng Wang, Yen-Lin Lu, I-Shing Yu, Yu-Yin Shih, Yung-Ming Jeng, Wen-Ming Hsu, Hsinyu Lee   +10 more
doaj   +1 more source